Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EBT (2022 - 2025)

CervoMed (CRVO) has disclosed EBT for 9 consecutive years, with -$8.1 million as the latest value for Q4 2025.

  • Quarterly EBT fell 20.6% to -$8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.0 million through Dec 2025, down 65.49% year-over-year, with the annual reading at -$27.0 million for FY2025, 65.49% down from the prior year.
  • EBT hit -$8.1 million in Q4 2025 for CervoMed, down from -$7.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$1.2 million in Q2 2023 to a low of -$8.1 million in Q4 2025.
  • Historically, EBT has averaged -$4.2 million across 4 years, with a median of -$4.1 million in 2022.
  • Biggest five-year swings in EBT: soared 71.05% in 2023 and later plummeted 184.05% in 2024.
  • Year by year, EBT stood at -$4.1 million in 2022, then surged by 42.06% to -$2.4 million in 2023, then plummeted by 184.05% to -$6.7 million in 2024, then dropped by 20.6% to -$8.1 million in 2025.
  • Business Quant data shows EBT for CRVO at -$8.1 million in Q4 2025, -$7.7 million in Q3 2025, and -$6.2 million in Q2 2025.